DocuGuru
Taylor & Francis

Expert Opinion on Therapeutic Targets Template

Write in a clean editor, then format for Expert Opinion on Therapeutic Targets in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.

Use this template

About the Expert Opinion on Therapeutic Targets format

Expert Opinion on Therapeutic Targets is a peer-reviewed journal published by Taylor & Francis, covering Cytokine Signaling Pathways and Interactions, MicroRNA in disease regulation, PI3K/AKT/mTOR signaling in cancer.

PublisherTaylor & Francis
Reference styleAuthor–year (Chicago, T&F)
Author–year — (Smith, 2023) in the text
Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Expert Opinion on Therapeutic Targets 12 (3): 45–58.

Formats any DOI in Expert Opinion on Therapeutic Targets style. No sign-up.

Publishes research inCytokine Signaling Pathways and Interactions MicroRNA in disease regulation PI3K/AKT/mTOR signaling in cancer Ion channel regulation and function Peptidase Inhibition and Analysis
ISSN1472-8222
Citation impact (2-yr)3.68
h-index129
i10-index1,861
Total citations101,532
Top institutions publishing hereWeatherford College
Journal websiteinformahealthcare.com
You getA submission-ready PDF and the editable LaTeX source — ready to submit.

Papers published in Expert Opinion on Therapeutic Targets per year

145
2014
163
2015
84
2016
107
2017
91
2018
78
2019
110
2020
80
2021
82
2022
103
2023
86
2024
74
2025

Citation impact of Expert Opinion on Therapeutic Targets by publication year

6.2K
2014
6.7K
2015
4K
2016
5.2K
2017
5K
2018
3.5K
2019
4.1K
2020
1.7K
2021
1.5K
2022
1.4K
2023
589
2024
164
2025

Citations each year’s papers have accumulated so far — the most recent years are still building up.

Most-cited papers in Expert Opinion on Therapeutic Targets

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

Libero Santarpia, Scott M. Lippman, Adel K. El‐Naggar · 1 Jan 2012

INTRODUCTION: The MAPK pathway comprises several key signaling components and phosphorylation events that play a role in tumorigenesis. These activated kinases transmit extracellular signals that regulate cell growth, differentiation, proliferation, apoptosis and migration functions. Alteration of the RAS-RAF-MEK-ERK-MAPK (RAS-MAPK) pathway has been reported in human cancer as a result of abnormal activation of receptor tyrosine…

1,038 citations Cite SaveGo to paper →
Targeting the EGFR signaling pathway in cancer therapy

Parthasarathy Seshacharyulu, Moorthy P. Ponnusamy, Dhanya Haridas et al. · 1 Jan 2012

INTRODUCTION: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and…

928 citations Cite SaveGo to paper →
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

Antonella De Luca, Monica R. Maiello, Amelia D’Alessio et al. · 23 Mar 2012

INTRODUCTION: The RAS/RAF/MAP kinase-ERK kinase (MEK)/extracellular-signal-regulated kinase (ERK) (MAPK) and the PI3K/AKT/mammalian target of rapamycin (mTOR) (PI3K) pathways are frequently deregulated in human cancer as a result of genetic alterations in their components or upstream activation of cell-surface receptors. These signalling cascades are regulated by complex feedback and cross-talk mechanisms. AREAS COVERED: In this review…

747 citations Cite SaveGo to paper →
Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase

Usune Etxeberría, Ana Laura de la Garza, Javier Campión et al. · 24 Feb 2012

INTRODUCTION: The increasing prevalence of type 2 diabetes mellitus and the negative clinical outcomes observed with the commercially available anti-diabetic drugs have led to the investigation of new therapeutic approaches focused on controlling postprandrial glucose levels. The use of carbohydrate digestive enzyme inhibitors from natural resources could be a possible strategy to block dietary carbohydrate…

392 citations Cite SaveGo to paper →
Targeting selectins and selectin ligands in inflammation and cancer

Steven R. Barthel, Jacyln D Gavino, Leyla Descheny et al. · 26 Oct 2007

Inflammation and cancer metastasis are associated with extravasation of leukocytes or tumor cells from blood into tissue. Such movement is believed to follow a coordinated and sequential molecular cascade initiated, in part, by the three members of the selectin family of carbohydrate-binding proteins: E-selectin (CD62E), L-selectin (CD62L) and P-selectin (CD62P). E-selectin is particularly noteworthy in…

391 citations Cite SaveGo to paper →

Expert Opinion on Therapeutic Targets template — frequently asked questions

How do I write a paper in the Expert Opinion on Therapeutic Targets format?
In DocuGuru you write your manuscript in a normal editor — no LaTeX setup required — and select the Expert Opinion on Therapeutic Targets template. When you export, DocuGuru compiles the paper into the official Taylor & Francis format and hands you a submission-ready PDF along with the editable LaTeX source.
What reference style does Expert Opinion on Therapeutic Targets use?
Expert Opinion on Therapeutic Targets uses Author–year (Chicago, T&F) references, shown as author–year markers such as (Smith, 2023) in the text. DocuGuru formats every in-text citation and the reference list in this exact style automatically. A reference appears like this: Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Expert Opinion on Therapeutic Targets 12 (3): 45–58.
Do I need to know LaTeX to submit to Expert Opinion on Therapeutic Targets?
No. DocuGuru generates the interact LaTeX class and compiles the PDF for you in the background, so you get a Taylor & Francis-ready Expert Opinion on Therapeutic Targets document without writing any LaTeX. If you do want it, the LaTeX source is included in the export.
Can I import an existing draft into the Expert Opinion on Therapeutic Targets template?
Yes. Paste or upload your current manuscript — Word, LaTeX, Markdown, or plain text — and DocuGuru reflows it into the Expert Opinion on Therapeutic Targets format with correct headings, figures, tables, and author–year citations.
Who publishes Expert Opinion on Therapeutic Targets?
Expert Opinion on Therapeutic Targets is a multidisciplinary journal published by Taylor & Francis. DocuGuru's Expert Opinion on Therapeutic Targets template matches Taylor & Francis's official submission format.
Can I export a submission-ready Expert Opinion on Therapeutic Targets PDF?
Yes — DocuGuru produces a PDF built with the official Expert Opinion on Therapeutic Targets template (the interact class) that is ready to submit to Taylor & Francis, together with the matching LaTeX source files.
How much does the Expert Opinion on Therapeutic Targets template cost?
You can start writing in the Expert Opinion on Therapeutic Targets template for free. Exporting the final submission-ready Expert Opinion on Therapeutic Targets PDF and LaTeX source is part of DocuGuru's paid plans — see the app for current pricing.
Use the Expert Opinion on Therapeutic Targets template